Eli Lilly's stock has seen a significant rise following the approval of its GLP-1 pill, intensifying competition in the weight-loss drug market with Novo Nordisk's Wegovy. Analysts continue to favor Eli Lilly's Foundayo, adding a financial dimension to the ongoing market battle and prompting investment discussions, with new approvals potentially marking a turning point for Novo Nordisk.

The U.S. Food and Drug Administration has approved Eli Lilly's new oral GLP-1 weight loss pill, Foundayo, offering a convenient alternative to injections and expanding market options while intensifying competition with Novo Nordisk's Wegovy.